## INF200

Cat. No.:	HY-155517		
Molecular F	rmula: C <sub>13</sub> H <sub>13</sub> ClN <sub>2</sub> O <sub>4</sub>		
Molecular W	eight: 296.71	ÇI	
Target:	NOD-like Receptor (NLR); Pyroptosis	N,	
Pathway:	Immunology/Inflammation; Apoptosis		
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	0 0	

Inhibitors

BIOLOGICAL ACTIVITY		
	DIGEOGICALACITY	
	Description	INF200 (compound 5) is a sulfonylurea-based inhibitor of NLRP3 and NLRP3-mediated pyroptosis. INF200 has beneficial cardiometabolic effects in rat model of high-fat diet (HFD)-induced metaflammation⊠and shows anti-inflammatory activity to (10 µM) decreases IL-1β release in human macrophages. INF200 improves glucose and lipid profiles⊠and attenuates systemic inflammation and biomarkers of cardiac dysfunction (particularly BNP). INF200 also improves myocardial damage-dependent ischemia/reperfusion injury (IRI) in hemodynamic evaluation <sup>[1]</sup> .
	IC <sub>50</sub> & Target	NLRP3 <sup>[1]</sup>

## REFERENCES

[1]. Gastaldi S, et al. Discovery of a novel 1,3,4-oxadiazol-2-one-based NLRP3 inhibitor as a pharmacological agent to mitigate cardiac and metabolic complications in an experimental model of diet-induced metaflammation. Eur J Med Chem. 2023 Sep 5;257:115542.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

## Product Data Sheet

